Previously called morbid obesity
Learn More A once-weekly, lower-dose agonist (GLP-1) designed for a gentler start and to minimize side effects
Currently, except for LIR and SMG, the numbers of related clinical studies of other GLP-1R agonists are few, especially in obese or overweight people without diabetes
In the SURMOUNT5 trial, participants lost an average of 20.2 % of their baseline body weight over 72 weeks with tirzepatide, with a greater proportion achieving weight-loss thresholds of 1525 % compared with semaglutide
How do I get the best results from Semaglutide GLP-1
Challenge your mind: Trying new hobbies, working through puzzles, and even playing music helps activate mental acuity and build cognitive resilience